Contrasting DICE Therapeutics (DICE) and Its Peers

DICE Therapeutics (NASDAQ:DICEGet Rating) is one of 952 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare DICE Therapeutics to related businesses based on the strength of its valuation, dividends, earnings, institutional ownership, risk, profitability and analyst recommendations.

Institutional & Insider Ownership

95.4% of DICE Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 4.3% of DICE Therapeutics shares are owned by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares DICE Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
DICE Therapeutics $1.13 million -$48.96 million -4.88
DICE Therapeutics Competitors $1.84 billion $245.93 million -3.87

DICE Therapeutics’ competitors have higher revenue and earnings than DICE Therapeutics. DICE Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares DICE Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DICE Therapeutics N/A -24.27% -22.74%
DICE Therapeutics Competitors -3,209.16% -160.26% -24.32%

Analyst Recommendations

This is a summary of current ratings and target prices for DICE Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DICE Therapeutics 0 0 6 0 3.00
DICE Therapeutics Competitors 3103 13051 39246 634 2.67

DICE Therapeutics currently has a consensus target price of $43.33, indicating a potential upside of 132.23%. As a group, “Pharmaceutical preparations” companies have a potential upside of 97.80%. Given DICE Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe DICE Therapeutics is more favorable than its competitors.


DICE Therapeutics beats its competitors on 7 of the 12 factors compared.

DICE Therapeutics Company Profile

(Get Rating)

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with's FREE daily email newsletter.